{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:27:40Z","timestamp":1791242860461,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overall survival (OS) is considered the reference-standard endpoint for assessing treatment efficacy in oncology but requires prolonged follow-up evaluation. This study assessed progression-free survival (PFS) as a surrogate endpoint for OS in patients with localized pancreatic ductal adenocarcinoma (PDAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective international multicenter study included patients with a diagnosis of localized PDAC who were treated with at least one cycle of (m)FOLFIRINOX (2012\u20132022). Surrogacy between PFS and OS was assessed at the individual level using the Kendall rank correlation coefficient (Kendall\u2019s\n                      <jats:italic>\u03c4<\/jats:italic>\n                      ), with a\n                      <jats:italic>\u03c4<\/jats:italic>\n                      of 0.8 considered the threshold for good surrogacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study analyzed 1783 patients with a median age of 64.0\u00a0years, and 43.4% underwent surgical resection. The median OS was 22.2\u00a0months, and the median PFS was 12.8\u00a0months. Kendall\u2019s\n                      <jats:italic>\u03c4<\/jats:italic>\n                      was 0.647 (95% confidence interval [CI], 0.626\u20130.668) overall and was higher for patients with lower baseline tumor burdens (primarily resectable [0.730], borderline resectable [0.640], locally advanced [0.601]), and more favorable pathologic responses (from 0.822 for ypT0 to 0.535 for ypT3\u20134, and from 0.755 for ypN0 to 0.541 for ypN2). The median post-progression survival was 6.7 months (interquartile range, 3.3\u201313.4\u00a0months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Individual-level surrogacy between PFS and OS did not meet the prespecified threshold for good surrogacy due to considerable interpatient variability in post-progression survival, supporting the continued use of OS as the gold-standard efficacy endpoint in clinical trials. However, surrogacy was stronger among patients with lower pretreatment tumor burdens and more favorable pathologic responses, potentially facilitating perioperative treatment development through shorter follow-up periods in pancreatic cancer trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20620-5","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:15Z","timestamp":1790375955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consortium Study"],"prefix":"10.1245","author":[{"given":"Jun","family":"Okui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc G.","family":"Besselink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice C.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas Groot","family":"Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Ceuppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther N.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Paniccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer H.","family":"Zureikat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew H. G.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhiko","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"20620_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.\u00a0https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"20620_CR2","doi-asserted-by":"publisher","first-page":"e073995","DOI":"10.1136\/bmj-2022-073995","volume":"383","author":"M Del Chiaro","year":"2023","unstructured":"Del Chiaro M, Sugawara T, Karam SD, Messersmith WA. Advances in the management of pancreatic cancer. BMJ. 2023;383:e073995.\u00a0https:\/\/doi.org\/10.1136\/bmj-2022-073995.","journal-title":"BMJ"},{"key":"20620_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer. Lancet. 2025;405:1182\u2013202.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(25)00261-2.","journal-title":"Lancet"},{"key":"20620_CR4","first-page":"1121","volume":"11","author":"A Delgado","year":"2021","unstructured":"Delgado A, Guddati AK. Clinical endpoints in oncology: a primer. Am J Cancer Res. 2021;11:1121\u201331.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/33948349\/.","journal-title":"Am J Cancer Res"},{"key":"20620_CR5","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1634\/theoncologist.2017-0152","volume":"22","author":"GM Blumenthal","year":"2017","unstructured":"Blumenthal GM, Kluetz PG, Schneider J, Goldberg KB, McKee AE, Pazdur R. Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies. Oncologist. 2017;22:762\u20137.\u00a0https:\/\/doi.org\/10.1634\/theoncologist.2017-0152.","journal-title":"Oncologist"},{"key":"20620_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006919","author":"J Okui","year":"2025","unstructured":"Okui J, Matsuda S, Nagashima K, et al. Recurrence-free survival as a surrogate endpoint for overall survival in resectable esophageal cancer: integrated analysis of individual patient data from phase trials. Ann Surg. 2025. https:\/\/doi.org\/10.1097\/sla.0000000000006919.","journal-title":"Ann Surg"},{"key":"20620_CR7","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/jnci\/djt270","volume":"105","author":"K Oba","year":"2013","unstructured":"Oba K, Paoletti X, Alberts S, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst. 2013;105:1600\u20137.\u00a0https:\/\/doi.org\/10.1093\/jnci\/djt270.","journal-title":"J Natl Cancer Inst"},{"key":"20620_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/0962280207081864","volume":"17","author":"M Buyse","year":"2008","unstructured":"Buyse M, Burzykowski T, Michiels S, Carroll K. Individual- and trial-level surrogacy in colorectal cancer. Stat Methods Med Res. 2008;17:467\u201375.\u00a0https:\/\/doi.org\/10.1177\/0962280207081864.","journal-title":"Stat Methods Med Res"},{"key":"20620_CR9","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26:1987\u201392.\u00a0https:\/\/doi.org\/10.1200\/JCO.2007.10.8407.","journal-title":"J Clin Oncol"},{"key":"20620_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","volume":"14","author":"A Mauguen","year":"2013","unstructured":"Mauguen A, Pignon JP, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data. Lancet Oncol. 2013;14:619\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(13)70158-X.","journal-title":"Lancet Oncol"},{"key":"20620_CR11","doi-asserted-by":"publisher","first-page":"e000766","DOI":"10.1136\/bmjonc-2025-000766","volume":"4","author":"LF Leite","year":"2025","unstructured":"Leite LF, Costa de Almeida LF, Diniz da Concei\u00e7\u00e3o L, et al. Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis. BMJ Oncol. 2025;4:e000766.\u00a0https:\/\/doi.org\/10.1136\/bmjonc-2025-000766.","journal-title":"BMJ Oncol"},{"key":"20620_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12885-020-06910-5","volume":"20","author":"RC Nie","year":"2020","unstructured":"Nie RC, Zou XB, Yuan SQ, et al. Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials. BMC Cancer. 2020;20:421. https:\/\/doi.org\/10.1186\/s12885-020-06910-5.","journal-title":"BMC Cancer"},{"key":"20620_CR13","doi-asserted-by":"publisher","first-page":"e1918939","DOI":"10.1001\/jamanetworkopen.2019.18939","volume":"3","author":"X Paoletti","year":"2020","unstructured":"Paoletti X, Lewsley LA, Daniele G, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e1918939. 2020;3(1):e1918939. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18939.","journal-title":"JAMA Netw Open"},{"key":"20620_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1159\/000542137","volume":"103","author":"T Araki","year":"2025","unstructured":"Araki T, Kawahira M, Shimokawa M, et al. Real-world analysis of the correlation between overall survival and progression-free survival in advanced pancreatic cancer: results of NAPOLEON-1 and 2 studies. Oncology. 2025;103:569\u201379.\u00a0https:\/\/doi.org\/10.1159\/000542137.","journal-title":"Oncology"},{"key":"20620_CR15","doi-asserted-by":"publisher","first-page":"znae033","DOI":"10.1093\/bjs\/znae033","volume":"111","author":"RT Theijse","year":"2024","unstructured":"Theijse RT, Stoop TF, Janssen QP, et al. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. Br J Surg. 2024;111:znae033. https:\/\/doi.org\/10.1093\/bjs\/znae033.","journal-title":"Br J Surg"},{"key":"20620_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.6004\/jnccn.2022.7008","volume":"20","author":"QP Janssen","year":"2022","unstructured":"Janssen QP, van Dam JL, Prakash LR, et al. Neoadjuvant radiotherapy after (m)FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: a TAPS Consortium study. J Natl Compr Canc Netw. 2022;20:783\u201391.\u00a0https:\/\/doi.org\/10.6004\/jnccn.2022.7008.","journal-title":"J Natl Compr Canc Netw"},{"key":"20620_CR17","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1245\/s10434-023-14680-0","volume":"31","author":"D Doppenberg","year":"2024","unstructured":"Doppenberg D, Stoop TF, van Dieren S, et al. Serum CEA as a prognostic marker for overall survival in patients with localized pancreatic adenocarcinoma and non-elevated CA19-9 levels treated with FOLFIRINOX as initial treatment: a TAPS Consortium study. Ann Surg Oncol. 2024;31:1919\u201332. https:\/\/doi.org\/10.1245\/s10434-023-14680-0.","journal-title":"Ann Surg Oncol"},{"key":"20620_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jnci\/djac018","volume":"114","author":"QP Janssen","year":"2022","unstructured":"Janssen QP, van Dam JL, Doppenberg D, et al. FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst. 2022;114:695\u2013703.\u00a0https:\/\/doi.org\/10.1093\/jnci\/djac018.","journal-title":"J Natl Cancer Inst"},{"key":"20620_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf011","author":"EN Dekker","year":"2025","unstructured":"Dekker EN, van Klaveren D, Verkolf EMM, et al. Carbohydrate antigen 19\u20139 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study. Br J Surg. 2025. https:\/\/doi.org\/10.1093\/bjs\/znaf011.","journal-title":"Br J Surg"},{"key":"20620_CR20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1200\/JCO.23.01311","volume":"42","author":"EN Dekker","year":"2024","unstructured":"Dekker EN, van Dam JL, Janssen QP, et al. Improved clinical staging system for localized pancreatic cancer using the ABC factors: a TAPS Consortium study. J Clin Oncol. 2024;42:1357\u201367.\u00a0https:\/\/doi.org\/10.1200\/JCO.23.01311.","journal-title":"J Clin Oncol"},{"key":"20620_CR21","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/jnci\/djag024","volume":"118","author":"EN Dekker","year":"2026","unstructured":"Dekker EN, van Klaveren D, Verkolf EMM, et al. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst. 2026;118:1108\u201314.\u00a0https:\/\/doi.org\/10.1093\/jnci\/djag024.","journal-title":"J Natl Cancer Inst"},{"key":"20620_CR22","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.\u00a0https:\/\/doi.org\/10.1371\/journal.pmed.0040297.","journal-title":"PLoS Med"},{"key":"20620_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","volume":"206","author":"MHG Katz","year":"2008","unstructured":"Katz MHG, Pisters PWT, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833\u201346.\u00a0https:\/\/doi.org\/10.1016\/j.jamcollsurg.2007.12.020.","journal-title":"J Am Coll Surg"},{"key":"20620_CR24","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Pancreatic adenocarcinoma V.2.2023. 2023. Retrieved 15 January 2026 at https:\/\/www.nccn.org."},{"key":"20620_CR25","volume-title":"AJCC Cancer Staging Manual","author":"S Kakar","year":"2016","unstructured":"Kakar S, Pawlik TM, Allen PJ. AJCC Cancer Staging Manual. 8th edn. Springer-Verlag; 2016.","edition":"8"},{"key":"20620_CR26","doi-asserted-by":"publisher","first-page":"znaf131","DOI":"10.1093\/bjs\/znaf131","volume":"112","author":"J Okui","year":"2025","unstructured":"Okui J, Nagashima K, Matsuda S, et al. Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials. Br J Surg. 2025;112:znaf131.\u00a0https:\/\/doi.org\/10.1093\/bjs\/znaf131.","journal-title":"Br J Surg"},{"key":"20620_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/biomet\/30.1-2.81","volume":"30","author":"MG Kendall","year":"1938","unstructured":"Kendall MG. A new measure of rank correlation. Biometrika. 1938;30:81.\u00a0https:\/\/doi.org\/10.2307\/2332226","journal-title":"Biometrika"},{"key":"20620_CR28","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1158\/1078-0432.CCR-22-2920","volume":"29","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Xie J, Valderrama A, et al. Event-free survival as a surrogate for overall survival in gastric and gastroesophageal junction adenocarcinoma: a meta-analysis in the neoadjuvant \u00b1 adjuvant setting. Clin Cancer Res. 2023;29:1360\u20137.\u00a0https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2920.","journal-title":"Clin Cancer Res"},{"key":"20620_CR29","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/sim.8001","volume":"38","author":"EM Weber","year":"2019","unstructured":"Weber EM, Titman AC. Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall\u2019s \u03c4. Stat Med. 2019;38:703\u201319.\u00a0https:\/\/doi.org\/10.1002\/sim.8001.","journal-title":"Stat Med"},{"key":"20620_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/1467-9876.00244","volume":"50","author":"T Burzykowski","year":"2001","unstructured":"Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc Ser C Appl Stat. 2001;50:405\u201322.\u00a0https:\/\/doi.org\/10.1111\/1467-9876.00244.","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"20620_CR31","doi-asserted-by":"publisher","DOI":"10.2202\/1557-4679.1121","author":"L Lakhal","year":"2009","unstructured":"Lakhal L, Rivest LP, Beaudoin D. IPCW estimator for Kendall\u2019s tau under bivariate censoring. Int J Biostat. 2009. https:\/\/doi.org\/10.2202\/1557-4679.1121.","journal-title":"Int J Biostat"},{"key":"20620_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360.\u00a0https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"20620_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pst.207","volume":"5","author":"T Burzykowski","year":"2006","unstructured":"Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat. 2006;5:173\u201386.\u00a0https:\/\/doi.org\/10.1002\/pst.207.","journal-title":"Pharm Stat"},{"key":"20620_CR34","unstructured":"Nagashima K. A sample size determination tool for two sample survival rank tests. Retrieved 26 December 2024 at https:\/\/nshi.jp\/en\/js\/twosurvyr\/."},{"key":"20620_CR35","doi-asserted-by":"publisher","first-page":"znae038","DOI":"10.1093\/bjs\/znae038","volume":"111","author":"J Okui","year":"2024","unstructured":"Okui J, Nagashima K, Matsuda S, et al. Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. Br J Surg. 2024;111:znae038.\u00a0https:\/\/doi.org\/10.1093\/bjs\/znae038.","journal-title":"Br J Surg"},{"key":"20620_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006269","author":"SH Cass","year":"2024","unstructured":"Cass SH, Tzeng CWD, Prakash LR, et al. Trends over time in recurrence patterns and survival outcomes after neoadjuvant therapy and surgery for pancreatic cancer. Ann Surg. 2024. https:\/\/doi.org\/10.1097\/SLA.0000000000006269.","journal-title":"Ann Surg"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20620-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20620-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20620-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:18Z","timestamp":1790375958000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20620-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":36,"alternative-id":["20620"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20620-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,26]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alice Wei received clinical trial funding from Histosonics; is a member of DSMB member; and received honoraria from Ipsen, Medtronics and AstraZeneca. Eileen O\u2019Reilly received research funding to her institution from Arcus, Genentech\/Roche, BioNTech, Incyte, AstraZeneca, Elicio Therapeutics, Digestive Care, Agenus, Amgen, Revolution Medicines, and Tango Therapeutics; participated in consulting\/DSMB activities (uncompensated) with Arcus, Actithera, Amgen, Astellas, AstraZeneca, Corcept, Pfizer, Agenus, BioNTech, Ipsen, Ikena, Merck, Immuneering, Moma Therapeutics, Novartis, BMS, Revolution Medicines, Regeneron, Systimmune, Tango Therapeutics, and Verastem; received travel support from BioNTech, Arcus, Pfizer, and Revolution Medicines; and had other relationships with the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Imedex, Research To Practice, Stand Up To Cancer (SU2C), NIH\/NCI, Break Through Cancer, and TouchIME; and support from Cancer Center Support Grant\/Core Grant P30 CA008748 and NCI\/NIH P50 CA257881-01A1.<PUB1>","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}